Skip to main content
U.S. flag

An official website of the United States government

Nobiletin, a citrus flavonoid, improves memory impairment and Abeta pathology in a transgenic mouse model of Alzheimer's disease

Bibliographic

Year of Publication:
2008
Contact PI Name:
Tohru Yamakuni
Contact PI Affiliation:
Department of Pharmaceutical Molecular Biology, Graduate School of Pharmaceutical Sciences Tohoku University, Japan
Co-Authors:
Hiroshi Onozuka, Akira Nakajima, Kentaro Matsuzaki, Ryong-Woon Shin, Koichi Ogino, Daisuke Saigusa, Naomi Tetsu, Akihito Yokosuka, Yutaka Sashida, Yoshihiro Mimaki, Yasushi Ohizumi
Primary Reference (PubMED ID):
Funding Source:
Japanese Ministry of Health, Labour and Welfare
Takeda Science Foundation
Study Goal and Principal Findings:

Increasing evidence suggests that the elevation of beta-amyloid (Abeta) peptides in the brain is central to the pathogenesis of Alzheimer's disease (AD). Our recent studies have demonstrated that nobiletin, a polymethoxylated flavone from citrus peels, enhances cAMP/protein kinase A/extracellular signal-regulated kinase/cAMP response element-binding protein signaling in cultured hippocampal neurons and ameliorates Abeta-induced memory impairment in AD model rats. For the first time, we report that this natural compound improves memory deficits in amyloid precursor protein (APP) transgenic mice that overexpress human APP695 harboring the double Swedish and London mutations [APP-SL 7-5 transgenic (Tg) mice]. Our enzyme-linked immunosorbent assay (ELISA) also showed that administration of nobiletin to the transgenic mice for 4 months markedly reduced quantity of guanidine-soluble Abeta(1-40) and Abeta(1-42) in the brain. Furthermore, consistent with the results of ELISA, by immunohistochemistry with anti-Abeta antibody, it was evidently shown that the administration of nobiletin decreased the Abeta burden and plaques in the hippocampus of APP-SL 7-5 Tg mice. These findings suggest that this natural compound has potential to become a novel drug for fundamental treatment of AD.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Natural Product
Therapeutic Agent:
Nobiletin
Therapeutic Target:
Multi Target

Animal Model

Model Information:
Species:
Mouse
Model Type:
APP
Strain/Genetic Background:
C57BL/6

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Open Field Test
Contextual Fear Conditioning
Histopathology
beta Amyloid Load
beta Amyloid Deposits
Biochemical
Brain-beta Amyloid Peptide-Total
Brain-Guanidine Soluble beta Amyloid Peptide 40
Brain-Guanidine Soluble beta Amyloid Peptide 42
phospho-Extracellular Signal-Regulated Kinase (phospho-ERK)
Extracellular Signal-Regulated Kinase (ERK)
Immunochemistry
Brain-beta Amyloid Deposits
Pharmacokinetics
Blood Brain Barrier Penetration
Toxicology
General Behavior